Latest vemurafenib Stories
- Array to receive global rights from Novartis to innovative BRAF inhibitor - BOULDER, Colo., Jan. 23, 2015 /PRNewswire/ -- Array BioPharma Inc.
NEW YORK, Oct.
- Median overall survival is encouraging for this patient population - BOULDER, Colo., Sept.
The Highest Percentage of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next One to Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass.,
SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that K.
MADISON, N.J., June 10, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today introduced a new cancer test service based
In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.